- Clone:
- REA1543 | L-27
- Type of antibody:
- Recombinant antibodies, Primary antibodies
- Isotype:
- recombinant human IgG1
- Applications:
- MICS, IF, IHC Glossary
Related products for ENO1 Antibody, anti-human, REAfinity™
REA1543 recognizes the glycolytic enzyme Enolase 1 (ENO1), which is commonly known as alpha-enolase. It catalyzes the conversion of 2-phospho-3-subprocesses of glycolysis: 2-phosphoglycerate to phosphoenolpyruvate (PEP).
During stress or infection, ENO1 can function as a glycoprotein and plasminogen receptor on the cell surface and be involved in pathway actions such as migration, invasion, and plasminogen activation. Furthermore, it is involved in late glycolysis steps and binds to RNA in certain contexts (RNA binding, moonlighting functions). ENO1 is ubiquitously expressed; it is a basic enzyme of glycolysis in almost all tissues. Higher expression is often found in tissues with high glycolytic activity, such as the brain, skeletal muscle, erythrocytes, and tumor tissue. At the cellular level, ENO1 can occur both as an enzyme in the cytosol and as a surface protein in certain cell types, especially under pathogenic or stress conditions. Single-cell analysis reveals cell-specific differences: typically higher expression levels in cells with active glycolytic metabolism; ENO1 may also be prominently expressed in nerve tissue.
ENO1L1, MBPB1, MPB1, Alpha-enolase
Technical specifications
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
You have previously chosen International as your location.
What do you want to do?